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RACIAL DIFFERENCES IN PHARMACOTHERAPY AND HEALTH
CARE EXPENDITURES FOR THE TREATMENT OF ASTHMA IN
A MEDICAID POPULATION
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1The MEDSTAT Group, Inc, Ann Arbor, MI, USA; 2GlaxoSmithKline,
RTP, NC, USA; 3The MEDSTAT Group, Inc, Cambridge, MA, USA;
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OBJECTIVES: To compare pharmacotherapy and health care
expenditures by race for asthma patients in a Medicaid popula-
tion. METHODS: This analysis used the MarketScan® claims
and eligibility data for a multistate Medicaid population between
1999–2000. Because Medicaid eligibility is updated monthly, 24
monthly ﬁles were constructed to capture all Medicaid asthmatic
patients in 1999 and 2000. Patients were included in the study
if they had an asthma diagnosis or prescription for an asthma-
related drug in any given month. Patients were grouped by race,
a variable often not found in health care claims data sets. Type
of pharmacotherapy, demographics, health status, health care
utilization, and expenditures were measured to assess differences
between the racial groups. Descriptive analysis was used to deter-
mine medication use and health care costs across racial cohorts.
RESULTS: A total of 2,724,008 subjects were eligible for eval-
uation over the 2 year observational period. Overall, patients
used 1.8 times as many rescue medications compared to long
term controller medications per month. Hispanics used 2.5 times
more rescue medications. African-Americans (AA) used 2 times
more rescue medications, and Caucasians used 1.6 times more
rescue medications. Compared to Caucasians, asthma-related
drug expenditures were 20% and 69% lower for AA and His-
panics respectively. However, asthma-related inpatient costs were
94% higher for AA and 58% higher for Hispanics compared to
Caucasians. Similarly, asthma-related emergency room (ER)
costs were 48% higher for AA and 13% higher for Hispanics
compared to Caucasians. Overall, the largest component of the
asthma care among all groups was pharmacotherapy, at 50% of
total asthma expenditures ($64 per month). CONCLUSIONS:
Long-term controller asthma medications were underused by all,
but more so among minorities. This difference in use was
reﬂected in the cost of inpatient and ER asthma care across the
racial cohorts.
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HEALTH CARE EXPENDITURES OF PATIENTS WITH
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OBJECTIVES: To review the health care expenditures of patients
with comorbid allergic rhinitis (AR) and asthma, and determine
if AR treatment offsets the costs of asthma of these patients.
METHODS: A retrospective analysis was performed using the
MarketScan claims databases. The study population consisted of
privately insured and Medicare patients diagnosed with AR (N
= 347,363) in 1999 or 2000. Patients with at least two outpa-
tient prescriptions for asthma medication, or a diagnosis of
asthma and at least one outpatient prescription for asthma med-
ication, were classiﬁed as having asthma. Asthma-related health
care expenditures were accumulated over a 12-month follow-up
period. Expenditures among treated AR patients were compared
to untreated AR patients. RESULTS: Approximately 16% of AR
patients had comorbid asthma. The majority (90.8%) of these
patients received at least one AR treatment of a nonsedating anti-
histamine, inhaled nasal corticosteroid, or inhaled antihistamine
during the 12 month follow-up period. Patients without AR
treatment had mean annual asthma-related emergency room
(ER), inpatient, and outpatient expenditures of $24 (127 S.D.),
$201 (3340 S.D.), and $240 (561 S.D.), respectively. Compared
to untreated AR patients, persons receiving AR treatment had
signiﬁcantly lower mean annual asthma-related costs (p < 0.05)
for ER, inpatient and outpatient expenditures, $18 (151 S.D.),
$114 (1575 S.D.), and $181 (588 S.D.), respectively. Costs 
of outpatient prescription drug for asthma were higher among
AR-treated patients than untreated ($447 vs. $355, p < 0.05),
nevertheless, mean total asthma costs for AR-treated patients
were $760 (1931 S.D.), signiﬁcantly lower than for untreated
patients, $820 (3515 S.D.). AR-treated asthma patients also had
lower asthma expenditures compared to the untreated after con-
trolling for differences in demographics, comorbidities, and
asthma severity. CONCLUSIONS: Asthma is a common comor-
bidity of AR. Use of AR drug treatment may offset some asthma
expenditures.
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OBJECTIVES: To evaluate medical expenditures for asthma care
based on whether a health care plan requires enrolled members
to have a primary care provider (PCP). METHODS: The data
were drawn from the MEDSTAT MarketScan database. The
sample included 184,892 patients with either at least one hospi-
talization or at least two outpatient visits for asthma during
1998–2001. Approximately 51 percent (94150) of the sample
were enrolled in health plans requiring a PCP (PCP plans), while
the remainder were enrolled in plans not requiring a PCP (NPCP
plans). We used a log-linear regression analysis to examine dif-
ferences in expenditures between plan types, controlling for
gender, age, region, industry and dependent status. All differ-
ences are signiﬁcant at p < 0.001. RESULTS: Total per capita
medical expenditures were signiﬁcantly higher for NPCP ($730)
than for PCP plans ($598). Both hospital ($170 versus $88) and
outpatient ($355 versus $306) expenditures were signiﬁcantly
higher for NPCP than for PCP plans with no signiﬁcant differ-
ences in prescription drug expenditures ($205 versus $204). For
patients hospitalized at least once these differences in expendi-
tures were larger; with mean total expenditures of $7040 for
NPCP versus $5626 for PCP plans, and with 31 percent differ-
ences in hospitalization costs ($6084 versus $4640). On the
other hand, the average numbers of hospital readmissions for
asthma were signiﬁcantly higher (0.03 versus 0.02) for NPCP
than for PCP plans as was the average length of hospital stay
(4.02 versus 3.52 days). However, the number of outpatient visits
were signiﬁcantly lower for NPCP (5.67) than for PCP (5.97)
plans. CONCLUSION: Patients in PCP plans have fewer and
shorter hospitalizations and they visit outpatient clinics more fre-
quently. Although differential enrollment by severity cannot be
excluded, PCP plans not only cost less but might also provide
better asthma management for patients.
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